Microcap Ledger Moleculin Biotech, Inc. $MBRX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Houston, TX
- Fiscal year end
- December 31
- Shares outstanding
- 19,477,380 [10-Q 2026-08-13]
What the company doesAI summary of filing
Moleculin Biotech is a late-stage pharmaceutical development company evaluating drug candidates for hard-to-treat cancers and viruses. The company's lead program, Annamycin (naxtarubicin), is a next-generation anthracycline currently in a Phase 2B/3 pivotal trial called MIRACLE for relapsed/refractory acute myeloid leukemia in combination with cytarabine; the company also has two additional drug candidate portfolios (WP1066 and WP1122) in clinical and preclinical development funded by academic investigators. Moleculin is pre-revenue and operates through sponsored research agreements and clinical trial programs with the University of Texas MD Anderson Cancer Center and other academic institutions. [10-K 2026-03-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$20.48M | −$12.77M | $7.26M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $0.00 | $33.56M | −$22.73M | $8.88M | [10-K 2026-03-18] |
| FY ended Dec 2024 | $0.00 | $26.05M | −$23.86M | $4.28M | [10-K 2026-03-18] |
- Quarterly cash burn
- −$6.38M
- Cash runway Estimate
- ~3.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 3,001,895 | [10-Q 2024-11-08] |
| 2025-03-13 | 14,000,494 | [10-K/A 2025-04-30] |
| 2025-05-06 | 14,127,494 | [10-Q 2025-05-13] |
| 2025-08-05 | 30,286,168 | [10-Q 2025-08-12] |
| 2025-11-07 | 50,910,476 | [10-Q 2025-11-13] |
| 2026-03-11 | 5,336,350 | [10-K/A 2026-04-14] |
| 2026-05-07 | 5,336,350 | [10-Q 2026-05-14] |
| 2026-08-06 | 19,477,380 | [10-Q 2026-08-13] |
- Shelf registration
- S-1 filed 2026-07-29; declared effective 2026-07-31 [S-1 2026-07-29]
Listing status
Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-18. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-18 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-18] |
| 2025-11-21 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-11-21] |
| 2025-06-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-27] |
| 2025-05-23 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-23] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-03 | Foster Jonathan P. | buy | 293,333 | — | [4 2026-08-05] |
| 2026-08-03 | Klemp Walter V | buy | 533,333 | — | [4 2026-08-05] |
| 2026-08-03 | Picker Donald H | buy | 173,333 | — | [4 2026-08-05] |
| 2026-06-22 | Picker Donald H | exercise | 71 | — | [4 2026-06-24] |
| 2026-06-22 | Picker Donald H | other | 21 | $3.12 | [4 2026-06-24] |
| 2026-06-22 | Klemp Walter V | exercise | 360 | — | [4 2026-06-24] |
| 2026-06-22 | Klemp Walter V | other | 88 | $3.12 | [4 2026-06-24] |
| 2026-06-22 | Foster Jonathan P. | exercise | 174 | — | [4 2026-06-24] |
| 2026-06-22 | Foster Jonathan P. | other | 41 | $3.12 | [4 2026-06-24] |
| 2026-06-20 | Picker Donald H | exercise | 44 | — | [4 2026-06-24] |
| 2026-06-20 | Picker Donald H | other | 13 | $2.88 | [4 2026-06-24] |
| 2026-06-20 | Klemp Walter V | exercise | 150 | — | [4 2026-06-24] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Director or officer change; Shareholder vote results |
| 2026-10-05 | 8-K | Regulation FD disclosure |
| 2026-09-29 | 8-K | Regulation FD disclosure |
| 2026-09-28 | 8-K | Regulation FD disclosure |
| 2026-09-25 | 8-K | Regulation FD disclosure |
| 2026-09-23 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-18 | 8-K | Listing notice or transfer |
| 2026-09-14 | 8-K | Regulation FD disclosure |
| 2026-08-31 | 8-K | Regulation FD disclosure |
| 2026-08-25 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-08-25 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-08-24 | DEF 14A | Proxy statement |
Alerts for $MBRX
Email me when Moleculin Biotech, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.